Hong Kong has often been the default trade vehicle for European consumer health brands selling into China online. That default is worth testing now that mainland cross-border e-commerce can run without a Hong Kong seller in the chain.
The useful question is not whether a Hong Kong company is required, but which structure fits the product, the cash cycle, and how much control and product-safety responsibility the brand is prepared to take.
Five practical points
- 1Before choosing a structure, check whether the product can use CBEC at all: it has to be on the positive list, stay in a direct-to-consumer channel, and sit within the transaction and annual value limits.
- 2The official CBEC seller must be an overseas-registered company that holds title and sells directly to the mainland consumer. A mainland subsidiary cannot play that role.
- 3One common model is to sell to a Hong Kong trading company that becomes the seller of record. If the brand is paid on shipment, cash pressure falls, but an extra logistics step appears and product-safety duty sits with the Hong Kong company.
- 4The same Hong Kong seller can ship straight into a mainland bonded warehouse. That saves a physical stop, but only works if title, money and logistics stay consistent. A pass-through invoicing entity is a risk, not an advantage.
- 5The brand, or an overseas entity it designates, can also be the seller, with a mainland operator that does not take title. That gives more control, and more inventory, cash and product-safety responsibility. No model is inherently best: choose the one that matches the brand's China ambition and who actually creates value in the chain.